LightLab Highlights OCT Market Leadership at SCAI | LightLab Imaging, Inc.
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News LightLab Imaging, Inc. LightLab Highlights OCT Market Leadership at SCAI

LightLab Highlights OCT Market Leadership at SCAI

Company News - LightLab Imaging, Inc.

LightLab Imaging will exhibit at the Society for Cardiovascular Angiography and Interventions (SCAI) meeting in San Diego, CA May 5 to 8, in booth 28.

LightLab Imaging, Inc., the pioneer in development and world leader in sales of Optical Coherence Tomography (OCT) systems for vascular and other imaging applications, will exhibit at the Society for Cardiovascular Angiography and Interventions (SCAI) meeting in San Diego, CA May 5 to 8, in booth 28.

Presenting at SCAI will be Marco A Costa, MD, PhD, Professor of Medicine Director, Interventional Cardiovascular Center and Director, Research and Innovation Center at the Harrington-McLaughlin Heart and Vascular Institute University Hospitals, Case Western Reserve University. He will deliver the talk, "Do I really need to see that much stent detail with OCT?" on Wednesday, May 5, from 11:00 AM to 11:15 AM.

"Cardiologists have long been searching for imaging tools to enhance our understanding of vascular disease and guide optimal PCI and other coronary therapeutic strategies," said Dr. Costa. "The LightLab's C7-XR imaging system is the first non-occlusive optical intravascular imaging system already available in Europe and Asia. Many have focused on the eye catching micron-level vascular images, but "ease-of-use" and speed at > 100 frames/sec are the key features of this imaging tool that will revolutionize the way real-world interventionalists approach coronary artery disease."

Dr. Costa directs the cardiovascular imaging core lab responsible for analyzing results from many trials using OCT. LightLab has submitted a 510(k) Premarket Notice which is under review by the Food and Drug Administration. LightLab OCT is not currently cleared for sale in the US.

Working with leading physicians worldwide, LightLab has led the clinical development of intravascular OCT applications and currently offers the only commercially available OCT systems. The company's FD-OCT or Frequency Domain OCT system has been available outside of the U.S. for the past year. LightLab's C7-XR systems are installed in many European countries, and thousands of FD-OCT imaging procedures have been performed with this system since its introduction.

"SCAI is an important show for LightLab and a great opportunity for us to demonstrate the clinical advantages of our products," said David Kolstad, CEO of LightLab Imaging. "The C7-XR system has provided clinicians in Europe a significant advancement in imaging speed and clinical data available to them during therapeutic procedures."

Source: LightLab